AustralieFrV1, PubMed, Corpus, bibRecord, 001808

P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Track: SCLC, Mesothelioma, Thymoma.

Identifieur interne : 001808 ( PubMed/Corpus ); précédent : 001807; suivant : 001809

P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Track: SCLC, Mesothelioma, Thymoma.

Auteurs : Giorgio V. Scagliotti ; Rabab Gaafar ; Anna Nowak ; Nicholas J. Vogelzang ; Ute Von Wangenheim ; Nassim Morsli ; Derek Velema ; Sanjay Popat

Source :

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [ 1556-1380 ] ; 2016.

RBID : pubmed:27676538
DOI: 10.1016/j.jtho.2016.08.075
PubMed: 27676538

Links to Exploration step

pubmed:27676538

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Track: SCLC, Mesothelioma, Thymoma.</title>
<author><name sortKey="Scagliotti, Giorgio V" sort="Scagliotti, Giorgio V" uniqKey="Scagliotti G" first="Giorgio V" last="Scagliotti">Giorgio V. Scagliotti</name>
<affiliation><nlm:affiliation>Department of Oncology, University of Turin, Torino/ITALY.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gaafar, Rabab" sort="Gaafar, Rabab" uniqKey="Gaafar R" first="Rabab" last="Gaafar">Rabab Gaafar</name>
<affiliation><nlm:affiliation>National Cancer Institute, Cairo University, Cairo/EGYPT.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Nowak, Anna" sort="Nowak, Anna" uniqKey="Nowak A" first="Anna" last="Nowak">Anna Nowak</name>
<affiliation><nlm:affiliation>School of Medicine And Pharmacology Qeii, Medical Centre Unit, University of Western Australia, Crawley/WA/AUSTRALIA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vogelzang, Nicholas J" sort="Vogelzang, Nicholas J" uniqKey="Vogelzang N" first="Nicholas J" last="Vogelzang">Nicholas J. Vogelzang</name>
<affiliation><nlm:affiliation>US Oncology Comprehensive Cancer Centers of Nevada, Las Vegas/NV/UNITED STATES OF AMERICA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Von Wangenheim, Ute" sort="Von Wangenheim, Ute" uniqKey="Von Wangenheim U" first="Ute" last="Von Wangenheim">Ute Von Wangenheim</name>
<affiliation><nlm:affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach/GERMANY.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Morsli, Nassim" sort="Morsli, Nassim" uniqKey="Morsli N" first="Nassim" last="Morsli">Nassim Morsli</name>
<affiliation><nlm:affiliation>Boehringer Ingelheim France S.A.S., Paris/FRANCE.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Velema, Derek" sort="Velema, Derek" uniqKey="Velema D" first="Derek" last="Velema">Derek Velema</name>
<affiliation><nlm:affiliation>Boehringer Ingelheim (Canada) Ltd./Ltée, Burlington/ON/CANADA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Popat, Sanjay" sort="Popat, Sanjay" uniqKey="Popat S" first="Sanjay" last="Popat">Sanjay Popat</name>
<affiliation><nlm:affiliation>Royal Marsden Hospital NHS Foundation Trust, London and Surrey/UNITED KINGDOM.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27676538</idno>
<idno type="pmid">27676538</idno>
<idno type="doi">10.1016/j.jtho.2016.08.075</idno>
<idno type="wicri:Area/PubMed/Corpus">001808</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001808</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Track: SCLC, Mesothelioma, Thymoma.</title>
<author><name sortKey="Scagliotti, Giorgio V" sort="Scagliotti, Giorgio V" uniqKey="Scagliotti G" first="Giorgio V" last="Scagliotti">Giorgio V. Scagliotti</name>
<affiliation><nlm:affiliation>Department of Oncology, University of Turin, Torino/ITALY.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Gaafar, Rabab" sort="Gaafar, Rabab" uniqKey="Gaafar R" first="Rabab" last="Gaafar">Rabab Gaafar</name>
<affiliation><nlm:affiliation>National Cancer Institute, Cairo University, Cairo/EGYPT.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Nowak, Anna" sort="Nowak, Anna" uniqKey="Nowak A" first="Anna" last="Nowak">Anna Nowak</name>
<affiliation><nlm:affiliation>School of Medicine And Pharmacology Qeii, Medical Centre Unit, University of Western Australia, Crawley/WA/AUSTRALIA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Vogelzang, Nicholas J" sort="Vogelzang, Nicholas J" uniqKey="Vogelzang N" first="Nicholas J" last="Vogelzang">Nicholas J. Vogelzang</name>
<affiliation><nlm:affiliation>US Oncology Comprehensive Cancer Centers of Nevada, Las Vegas/NV/UNITED STATES OF AMERICA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Von Wangenheim, Ute" sort="Von Wangenheim, Ute" uniqKey="Von Wangenheim U" first="Ute" last="Von Wangenheim">Ute Von Wangenheim</name>
<affiliation><nlm:affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach/GERMANY.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Morsli, Nassim" sort="Morsli, Nassim" uniqKey="Morsli N" first="Nassim" last="Morsli">Nassim Morsli</name>
<affiliation><nlm:affiliation>Boehringer Ingelheim France S.A.S., Paris/FRANCE.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Velema, Derek" sort="Velema, Derek" uniqKey="Velema D" first="Derek" last="Velema">Derek Velema</name>
<affiliation><nlm:affiliation>Boehringer Ingelheim (Canada) Ltd./Ltée, Burlington/ON/CANADA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Popat, Sanjay" sort="Popat, Sanjay" uniqKey="Popat S" first="Sanjay" last="Popat">Sanjay Popat</name>
<affiliation><nlm:affiliation>Royal Marsden Hospital NHS Foundation Trust, London and Surrey/UNITED KINGDOM.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</title>
<idno type="eISSN">1556-1380</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">27676538</PMID>
<DateCreated><Year>2016</Year>
<Month>09</Month>
<Day>27</Day>
</DateCreated>
<DateRevised><Year>2016</Year>
<Month>09</Month>
<Day>27</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-1380</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>11</Volume>
<Issue>10S</Issue>
<PubDate><Year>2016</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</Title>
<ISOAbbreviation>J Thorac Oncol</ISOAbbreviation>
</Journal>
<ArticleTitle>P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Track: SCLC, Mesothelioma, Thymoma.</ArticleTitle>
<Pagination><MedlinePgn>S216</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S1556-0864(16)30784-5</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jtho.2016.08.075</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scagliotti</LastName>
<ForeName>Giorgio V</ForeName>
<Initials>GV</Initials>
<AffiliationInfo><Affiliation>Department of Oncology, University of Turin, Torino/ITALY.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gaafar</LastName>
<ForeName>Rabab</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>National Cancer Institute, Cairo University, Cairo/EGYPT.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nowak</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>School of Medicine And Pharmacology Qeii, Medical Centre Unit, University of Western Australia, Crawley/WA/AUSTRALIA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Vogelzang</LastName>
<ForeName>Nicholas J</ForeName>
<Initials>NJ</Initials>
<AffiliationInfo><Affiliation>US Oncology Comprehensive Cancer Centers of Nevada, Las Vegas/NV/UNITED STATES OF AMERICA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Von Wangenheim</LastName>
<ForeName>Ute</ForeName>
<Initials>U</Initials>
<AffiliationInfo><Affiliation>Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach/GERMANY.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Morsli</LastName>
<ForeName>Nassim</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Boehringer Ingelheim France S.A.S., Paris/FRANCE.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Velema</LastName>
<ForeName>Derek</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Boehringer Ingelheim (Canada) Ltd./Ltée, Burlington/ON/CANADA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Popat</LastName>
<ForeName>Sanjay</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Royal Marsden Hospital NHS Foundation Trust, London and Surrey/UNITED KINGDOM.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>09</Month>
<Day>22</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Thorac Oncol</MedlineTA>
<NlmUniqueID>101274235</NlmUniqueID>
<ISSNLinking>1556-0864</ISSNLinking>
</MedlineJournalInfo>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>9</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>9</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>9</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27676538</ArticleId>
<ArticleId IdType="pii">S1556-0864(16)30784-5</ArticleId>
<ArticleId IdType="doi">10.1016/j.jtho.2016.08.075</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001808 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001808 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:27676538
   |texte=   P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Track: SCLC, Mesothelioma, Thymoma.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:27676538" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Track: SCLC, Mesothelioma, Thymoma.

P2.01: LUME-MeSO: Phase II/III Study of Nintedanib + Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Track: SCLC, Mesothelioma, Thymoma.

Source :

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki